Company intelligence
1Cell.Ai Inc.
Ai-Powered Precision Oncology
About 1Cell.Ai Inc.
1Cell.Ai Inc. is a Precision Oncology Liquid Biopsy Diagnostics Company focused on developing the 1st-in-Class, Circulating Tumor Cell (CTC)-based, Single-Cell Multi-omics Lab Developed Tests for applications in clinical cancer care & early-stage clinical trials for Biotech/Pharma companies. 1Cell.Ai Inc. is a joint venture between two companies with innovative technologies: Actorius Innovations and Research Pvt Ltd, a leading provider of CTC Tests in India, and Indx.ai, a Silicon Valley based innovative software company specialising in Multi-omics Biomarker Data Analytics.
Verified activity
Signals from 1Cell.Ai Inc.
3 published signals
Legal & Regulatory
1Cell.Ai Inc. reported that the FDA approved the RAS-targeted drug daraxonoza (RASoque) for metastatic pancreatic cancer in a trial involving 300 patients with median overall survival at 6.7 months and near 2x longer survival.
Reported by 1Cell.Ai Inc.
Presence & Recognition
1Cell.Ai Inc. participated in LungCon 2026, organized by MOAR and the Kerala Association of Surgical Oncology (KASO) on September 6, 2026.
Reported by 1Cell.Ai Inc.
Research & Knowledge
1Cell.Ai Inc. published a study in Cancer Research, an AACR Journals, highlighting the potential of comprehensive ctDNA profiling in treatment-naïve patients with early-stage breast cancer.
Reported by 1Cell.Ai Inc.